羟甲唑啉鼻喷剂改善伴鼻阻塞OSAHS患者行nCPAP顺应性

Oxymetazoline nasal spray improved nCPAP compliance in obstructive sleep apnea-hypopnea syndrome patients with nasal obstruction

目的探讨羟甲唑啉鼻喷剂对伴鼻阻塞的阻塞性睡眠呼吸暂停低通气综合征(OSAHS)患者行经鼻持续气道正压通气(nCPAP)的疗效,明确伴鼻阻塞OSAHS患者改善鼻腔阻力提高nCPAP顺应性的意义。方法将确诊存在鼻阻塞性病变的OSAHS患者随机分为试验组30例(nCPAP治疗前使用羟甲唑啉喷雾剂)和对照组30例(常规使用nCPAP治疗),采用嗜睡评价量表(Epworth)、治疗压力滴定对nCPAP治疗前后睡眠情况进行分析。结果伴鼻阻塞的OSAHS患者羟甲唑啉喷雾后nCPAP治疗过程中的睡眠情况均较对照组改善,顺应性、依从性差异有统计学意义。结论羟甲唑啉鼻喷剂提高伴鼻阻塞的OSAHS患者nCPAP治疗顺应性,通过治疗有望获得患者对nCPAP治疗依从性的提高。

Objective To evaluate the effectiveness of oxymetazoline nasal spray in the treatment of obstructive sleep apnea-hypopnea syndrome （OSAHS） patients with nasal obstruction by nasal continuous positive airway pressure （nC PAP） therapy. Methods 60 patients diagnosed as moderate to severe OSAHS with nasal obstruction underwent a five night nCPAP therapy. They were ramandly divided into oxymetazoline therapy group and non-oxymetazoline therapy group before using nCPAP. The ESS score and the differences of effective nCPAP pressure before and after oxymetazo line therapy were analyzed. Results The ESS score were significant reduced after oxymetazoline therapy, with a sig nificant decreased effective treatment pressure. Conclusion Oxymetazoline nasal spray can reduce nCPAP pressure in the treatment of OSAHS patients with nasal obstruction, nCPAP compliance could be improved due to the reduction of the pressure.